胸腺肽α1对慢性阻塞性肺疾病急性发作患者免疫功能的影响  

The Effects of Thymosin α1 on Patients with Acute Attack of Chronic Obstructive Pulmonary Disease

作　　者：陈明清 胡玲[2] 

机构地区：[1]四川省医疗卫生服务指导中心,成都610041 [2]成都市第六人民医院,成都610051

出　　处：《国外医药（抗生素分册）》2016年第3期137-140,共4页World Notes on Antibiotics

摘　　要：目的探讨胸腺肽α1治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者疫功能的影响。方法选择符合标准的患者80例,根据入院先后顺序分为观察组和对照组各40例,两组患者根据指南均给予常规治疗,观察组在此基础上加用胸腺肽α1,比较两组患者治疗前后细胞免疫指标(CD3+、CD4+、CD8+及CD4+/CD8+)和体液免疫指标(Ig G、Ig A及Ig M)水平变化。结果治疗前,两组患者血清CD3+、CD4+、CD8+、CD4+/CD8+及Ig A、Ig G、Ig M水平均相似,差异无统计学意义(P>0.05);治疗2周后,两组患者血清CD3+、CD4+、CD8+、CD4+/CD8+及Ig A、Ig G、Ig M水平较本组治疗前均改善,差异有统计学意义(P<0.05);观察组改善幅度较对照组更显著,差异有统计学意义(P<0.05)。结论 AECOPD患者在常规治疗的基础上加用胸腺肽α1,可以增强患者免疫力,是一种有效的治疗措施。Objective Explore the effects of thymosin alon patients with acute exacerbation period of chronic obstructive pulmonary disease. Method Eighty selected patients who met the criteria were divided into observation group （n = 40） and control group （n = 40） according to the order of admission. Patients in both groups were on conventional therapy as defined by the guide, and those in the observation group were on additional thymosin-a1 based on this. Compare change level of cellular immunologic parameters （CD3＋, CD4＋, CD8＋ and CD4＋/CD8＋）and humoral immune parameters （IgG, IgA and IgM）of patients in the two groups before and after the treatment. Results Before the treatment, the levels of serum CD3＋, CD4＋, CD8＋, CD4＋/CD8＋ and IgA, IgG, IgM are similar, the difference is not statistically significant（P〉0.05）; 2 weeks after treatment, the levels of serum CD3＋, CD4＋, CD8＋, CD4＋/CD8＋ and IgA, IgG, IgM have significant improvements, compared with the levels of the group before the treatment, the difference is statistically significant （P〈0.05）; the improvement range of observation group is more outstanding than it in control group, the difference is statistically significant （P〈0.05）. Conclusions The addition of thymosin al for AECOPD patients on the basis of conventional treatment can enhance immunity of the patients and is a kind of effective treatment measure.

关 键 词：慢性阻塞性肺疾病急性加重期 胸腺肽A1 细胞免疫 体液免疫 

分 类 号：R979.5[医药卫生—药品]